Cancer treatment
AssigneeNuCana plc
InventorsDavid James Harrison, Mustafa Elshani
Life of this patent
Estimating the term…
Abstract
The invention provides NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate), a phosphoramidate derivative of 3′-deoxyadenosine, for use in the treatment of a proliferative disease, such as cancer, by reducing the amount of extra-cellular PD-L1 protein (e.g. soluble PD-L1 or exosomal PD L1) and/or increasing the amount of OX40-L. The invention also relates to the use of NUC-7738 in combination with an immune oncology agent such as an immune checkpoint inhibitor.
Claims20
A method for immunomodulation of an immune checkpoint protein in a human in need thereof comprising administration of an effective amount of a compound of the formula (NUC-7738):
- or a pharmaceutically acceptable salt thereof.
A method for inducing adaptive immunity against a proliferative disease in a human in need thereof comprising administering an effective amount of a compound of the formula (NUC-7738):
- or a pharmaceutically acceptable salt thereof.
A method of treating cancer in a human in need thereof comprising administration of a compound of the formula (NUC-7738):
- or a pharmaceutically acceptable salt thereof, in combination with pembrolizumab.
A method for treating a cancer that is resistant to checkpoint inhibitor therapy in a human in need thereof comprising administration of a compound of the formula (NUC-7738):
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.